Pfizer (PFE)

Sales/Maturities of Investments

$12.53B

TTM · Period ending: · USD

PFE logo

PFE Sales/Maturities of Investments

Latest reported$12.53B
PFE TTM Sales/Maturities of Investments ($197.20M → $12.53B)
High-resolution chart · PNG

PFE sales/maturities of investments history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Pfizer Sales/Maturities of Investments — Trailing twelve months (TTM) (USD)
Period endingSales/Maturities of Investments (USD)
12,525,000,000
23,317,000,000
22,690,000,000
22,065,000,000
20,228,000,000
11,908,000,000
8,834,000,000
41,132,000,000
50,430,000,000
36,191,000,000
46,417,000,000
22,034,000,000
26,634,000,000
43,178,000,000
48,871,000,000
50,617,000,000
44,013,000,000
39,257,000,000
28,096,000,000
20,106,000,000
15,468,000,000
15,042,000,000
12,730,000,000
9,196,000,000
10,611,000,000
10,163,000,000
16,340,000,000
20,786,000,000
17,679,000,000
17,948,000,000
19,908,000,000
20,312,000,000
20,565,000,000
20,646,000,000
15,959,000,000
17,563,000,000
31,989,000,000
37,992,000,000
40,690,000,000
43,145,000,000
43,151,000,000
44,436,000,000
52,761,000,000
58,685,000,000
59,102,000,000
64,808,000,000
57,449,000,000
56,196,000,000
56,127,000,000
51,375,000,000
48,682,000,000
43,968,000,000
35,785,000,000
30,537,000,000
31,751,000,000
30,472,000,000
26,450,000,000
26,947,000,000
27,197,000,000
21,018,000,000
15,079,000,000
11,653,000,000
14,874,000,000
31,387,000,000
51,112,000,000
59,558,000,000
54,643,000,000
52,095,000,000
41,445,000,000
37,546,000,000
36,805,000,000
28,142,000,000
26,432,000,000
25,495,000,000
30,460,000,000
27,028,000,000
24,841,000,000
22,386,000,000
21,004,000,000
21,829,000,000
28,236,000,000
35,543,000,000
28,088,000,000
29,268,000,000
21,760,000,000
12,851,000,000
13,293,000,000
9,895,000,000
10,282,000,000
12,936,000,000
12,416,000,000
11,607,000,000
13,575,000,000
12,326,000,000
13,258,000,000
16,971,000,000
15,848,000,000
14,703,000,000
12,808,000,000
8,964,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.